HCG (Human Chorionic Gonadotropin) — HCG 5000iu

Human Chorionic Gonadotropin (HCG) is a heterodimeric glycoprotein hormone indispensable for a wide range of endocrinological research. Structurally, HCG is composed of two dissimilar subunits, an alpha (α) and a beta (β) subunit, linked by non-covalent bonds. The α-subunit consists of 92 amino acids and is virtually identical to the alpha subunits of other glycoprotein hormones, including Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and Thyroid-Stimulating Hormone (TSH). The biological and receptor specificity of HCG is conferred by its unique β-subunit, which is composed of 145 amino acids and shares significant sequence homology with the β-subunit of LH. This structural mimicry allows HCG to bind to and activate the LH receptor with high affinity, making it a powerful tool for investigating LH-mediated signaling pathways.

The profound biological activity of HCG is heavily dependent on its glycosylation. Both subunits contain N-linked and O-linked carbohydrate moieties that are critical for proper protein folding, heterodimer assembly, plasma half-life, and signal transduction efficacy. The extended carboxy-terminal peptide on the β-subunit, which contains several O-linked glycosylation sites, is a key structural feature that distinguishes HCG from LH and contributes to its significantly longer circulatory half-life, a property of interest in various experimental models.

For researchers, HCG serves as a stable and potent agonist for the Luteinizing Hormone/Chorionic Gonadotropin Receptor (LHCGR). Its application in laboratory settings is extensive, primarily in studies focused on steroidogenesis, gonadal cell function, and the intricate mechanisms of the hypothalamic-pituitary-gonadal (HPG) axis. By providing a reliable method to stimulate the LHCGR, HCG allows for detailed investigation into downstream cellular events, from second messenger activation to gene transcription and steroid hormone synthesis in various preclinical models. Its availability as a high-purity, lyophilized peptide ensures consistency and reproducibility for demanding research applications.

Nexa Peptides provides HCG exclusively for laboratory and research purposes. This product is not intended for human or veterinary use. Its application should be confined to in vitro and in vivo research settings by qualified scientific professionals.

The primary mechanism of action for Human Chorionic Gonadotropin (HCG) is mediated through its high-affinity binding to the Luteinizing Hormone/Chorionic Gonadotropin Receptor (LHCGR). The LHCGR is a member of the G protein-coupled receptor (GPCR) superfamily, characterized by seven transmembrane domains. These receptors are predominantly expressed on the plasma membranes of specialized cells, most notably on testicular Leydig cells and ovarian theca, granulosa, and luteal cells. The expression of LHCGR has also been identified in various non-gonadal tissues in research models, suggesting a broader, though less understood, physiological role.

Upon binding of HCG to the extracellular domain of the LHCGR, a conformational change is induced in the receptor. This change facilitates the coupling and activation of an intracellular heterotrimeric G protein, primarily the stimulatory G protein, Gαs. Activation of Gαs leads to the dissociation of its GDP-bound alpha subunit, which then binds GTP and subsequently activates the membrane-bound enzyme adenylyl cyclase (AC). Activated AC catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP), a crucial second messenger in this signaling cascade.

The elevation of intracellular cAMP concentration is a pivotal event in HCG-mediated signaling. cAMP activates Protein Kinase A (PKA) by binding to its regulatory subunits, causing their dissociation from the catalytic subunits. The now-active PKA catalytic subunits phosphorylate a multitude of downstream protein targets on serine and threonine residues. In steroidogenic cells, a key substrate of PKA is the cAMP Response Element-Binding Protein (CREB), a transcription factor that, upon phosphorylation, translocates to the nucleus and modulates the expression of genes essential for steroidogenesis.

A critical PKA-mediated event is the phosphorylation and activation of the Steroidogenic Acute Regulatory (StAR) protein. The StAR protein facilitates the transport of cholesterol, the precursor for all steroid hormones, from the outer mitochondrial membrane to the inner mitochondrial membrane. This transport is the rate-limiting step in steroid hormone synthesis. Once inside the mitochondria, cholesterol is converted to pregnenolone by the enzyme cholesterol side-chain cleavage enzyme (P450scc). Pregnenolone then serves as the substrate for a series of enzymatic reactions within the smooth endoplasmic reticulum and mitochondria, ultimately leading to the synthesis of testosterone in Leydig cells or progesterone and estrogens in ovarian cells.

While the Gαs/cAMP/PKA pathway is the canonical and dominant signaling route for HCG, evidence from in vitro studies suggests that LHCGR can also couple to other G proteins, such as Gαq/11. This alternative pathway activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium from intracellular stores, while DAG activates Protein Kinase C (PKC). This parallel pathway can modulate cellular responses and may play a role in processes such as cell proliferation and differentiation, adding another layer of complexity to the molecular actions being investigated with HCG.

The unique ability of HCG to potently activate the LHCGR makes it an invaluable tool across several domains of biomedical research. Its primary application lies within the field of reproductive endocrinology, where it is used as a surrogate for Luteinizing Hormone (LH) in a variety of in vitro and in vivo experimental models. Researchers utilize HCG in Leydig and theca cell cultures to investigate the molecular machinery of steroidogenesis, studying the regulation of key enzymes, cholesterol transport mechanisms, and gene expression patterns following receptor activation. In animal models, HCG is frequently employed to study the physiological processes of ovulation, luteinization, and the maintenance of corpus luteum function, providing critical insights into the hormonal control of reproduction.

In studies involving models of hypogonadism, HCG is used to probe the functional capacity of gonadal steroidogenic cells. By administering HCG to animal models with compromised hypothalamic or pituitary function (secondary hypogonadism), researchers can directly assess the responsiveness of the testes or ovaries. These experiments help to differentiate between central and peripheral defects in the HPG axis and explore the potential for restoring endocrine function at the gonadal level. Such studies are fundamental to understanding the pathophysiology of various reproductive disorders.

Oncology research represents another significant area of investigation for HCG. The ectopic expression of LHCGR has been documented in various non-gonadal cancer cell lines and tumor tissues, including prostate, breast, endometrial, and adrenal cancers. Laboratory research focuses on elucidating the functional consequences of HCG-LHCGR signaling in these contexts. Studies using cell culture and xenograft models investigate whether HCG stimulation influences cancer cell proliferation, apoptosis, invasion, or angiogenesis. These mechanistic explorations aim to define the role, if any, of the HCG/LHCGR axis in tumor biology, potentially identifying novel signaling pathways relevant to carcinogenesis.

Furthermore, HCG is studied for its immunomodulatory properties, particularly in the context of reproductive immunology. As a hormone produced at high levels by the syncytiotrophoblast during pregnancy, it is hypothesized to play a role in establishing maternal immune tolerance to the semi-allogeneic fetus. In vitro research investigates the effects of HCG on various immune cell populations, such as T lymphocytes, dendritic cells, and uterine natural killer cells. These studies examine its impact on cytokine production, cell differentiation, and cytotoxic activity, aiming to unravel the mechanisms by which HCG may contribute to a successful pregnancy outcome. All such applications are strictly for preclinical research and are not for therapeutic or clinical use.